Drugs / DOR/3TC/TDF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05457530 Comparator | Aug 2022 → May 2023 | HIV infectious disease, abdominal obesity-metabolic syndrome, obesity disorder | Prism Health North Texas | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOR/3TC/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05457530 ↗ |
| Known as | TDF | “100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF” NCT05457530 ↗ |